Ramiro Sanchez - 07 Dec 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
CERE
Transactions as of
07 Dec 2023
Transactions value $
-$378,700
Form type
4
Filing time
11 Dec 2023, 16:17:09 UTC
Previous filing
08 Feb 2023
Next filing
19 Dec 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $35K +10K $3.50* 10K 07 Dec 2023 Direct F1
transaction CERE Common Stock Sale -$414K -10K -100% $41.37 0 07 Dec 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -10K -1.79% $0.00 548K 07 Dec 2023 Common Stock 10K $3.50 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person.
F2 25% of the shares subject to this option vested and became exercisable on January 14, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.